Becton Dickinson and Company (BDX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public…
Total Assets Chart for Becton Dickinson and Company
Becton Dickinson and Company (BDX) total assets for FY2025 were USD 55.3B, a -3.4% change from FY2024. Becton Dickinson and Company's total assets grew from USD 1.2B in 1985 to USD 55.3B in 2025 (4358.5% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 0.5%, 10-year CAGR of 7.5%, 20-year CAGR of 11.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $49.96B
- Implied Share Price
- $183.40
- Enterprise Value
- $66.05B
- Revenue (TTM)
- $22.48B
- EBITDA
- $6.12B
- Profit Margin
- 4.19%
- Trailing P/E
- 31.73
- Forward P/E
- 13.79
- Price/Book (MRQ)
- 2.05
- Price/Sales (TTM)
- 2.22
- EV/EBITDA
- 13.42
- EV/Revenue
- 2.94
- Dividend Yield
- 2.30%
- Book Value
- $89.64
- Free Cash Flow (FY2025)
- $2.67B
- Free Cash Flow Yield
- 5.34%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.